The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Expectorant Drug Market Research Report 2025
Synopsis
The global Expectorant Drug market was valued at US$ 325.6 million in 2023 and is anticipated to reach US$ 518.1 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
Growing Respiratory Disorders: With increasing pollution levels, smoking habits, and respiratory infections, the prevalence of respiratory disorders such as bronchitis, COPD (Chronic Obstructive Pulmonary Disease), and asthma is rising globally. This drives the demand for expectorant drugs as they help in clearing mucus from the respiratory tract.Preference for Natural Remedies: There's a growing trend towards natural and herbal expectorants as people become more health-conscious and seek alternatives to conventional medication. This trend might impact the market share of synthetic expectorants.Technological Advancements: Pharmaceutical companies are continuously investing in research and development to introduce more effective and safer expectorant formulations. This includes innovations in drug delivery systems to enhance the efficacy and convenience of expectorant medications.
This report aims to provide a comprehensive presentation of the global market for Expectorant Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Expectorant Drug.
Report Scope
The Expectorant Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Expectorant Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Expectorant Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Acella Pharmaceuticals LLC
Astrazeneca Plc.
Cipla Limited
Dabur India Ltd
Glenmark Pharmaceuticals Limited
lohnson and Johnson
Merck KGaA
Novartis International AG
Pfizer Inc.
Proctor and Gamble Co
Reckitt Benckiser Group plc
Sanofi SA
The Himalaya Drug Company
Perrigo Company plc
Vernalis plc
Tris Pharma Inc.
Aytu BioScience Inc.
Mayne Pharma Inc.
Taro Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals LLC
Aurobindo Pharma Ltd
GlaxoSmithKline plc.
Segment by Type
Oral Solid
Oral Liquid
Inhalants
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Expectorant Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Expectorant Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Expectorant Drug market was valued at US$ 325.6 million in 2023 and is anticipated to reach US$ 518.1 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
Growing Respiratory Disorders: With increasing pollution levels, smoking habits, and respiratory infections, the prevalence of respiratory disorders such as bronchitis, COPD (Chronic Obstructive Pulmonary Disease), and asthma is rising globally. This drives the demand for expectorant drugs as they help in clearing mucus from the respiratory tract.Preference for Natural Remedies: There's a growing trend towards natural and herbal expectorants as people become more health-conscious and seek alternatives to conventional medication. This trend might impact the market share of synthetic expectorants.Technological Advancements: Pharmaceutical companies are continuously investing in research and development to introduce more effective and safer expectorant formulations. This includes innovations in drug delivery systems to enhance the efficacy and convenience of expectorant medications.
This report aims to provide a comprehensive presentation of the global market for Expectorant Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Expectorant Drug.
Report Scope
The Expectorant Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Expectorant Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Expectorant Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Acella Pharmaceuticals LLC
Astrazeneca Plc.
Cipla Limited
Dabur India Ltd
Glenmark Pharmaceuticals Limited
lohnson and Johnson
Merck KGaA
Novartis International AG
Pfizer Inc.
Proctor and Gamble Co
Reckitt Benckiser Group plc
Sanofi SA
The Himalaya Drug Company
Perrigo Company plc
Vernalis plc
Tris Pharma Inc.
Aytu BioScience Inc.
Mayne Pharma Inc.
Taro Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals LLC
Aurobindo Pharma Ltd
GlaxoSmithKline plc.
Segment by Type
Oral Solid
Oral Liquid
Inhalants
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Expectorant Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Expectorant Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Expectorant Drug Market Overview
1.1 Product Overview and Scope of Expectorant Drug
1.2 Expectorant Drug Segment by Type
1.2.1 Global Expectorant Drug Market Value Comparison by Type (2024-2030)
1.2.2 Oral Solid
1.2.3 Oral Liquid
1.2.4 Inhalants
1.3 Expectorant Drug Segment by Application
1.3.1 Global Expectorant Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Expectorant Drug Market Size Estimates and Forecasts
1.4.1 Global Expectorant Drug Revenue 2019-2030
1.4.2 Global Expectorant Drug Sales 2019-2030
1.4.3 Global Expectorant Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Expectorant Drug Market Competition by Manufacturers
2.1 Global Expectorant Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Expectorant Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Expectorant Drug Average Price by Manufacturers (2019-2024)
2.4 Global Expectorant Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Expectorant Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Expectorant Drug, Product Type & Application
2.7 Expectorant Drug Market Competitive Situation and Trends
2.7.1 Expectorant Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Expectorant Drug Players Market Share by Revenue
2.7.3 Global Expectorant Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Expectorant Drug Retrospective Market Scenario by Region
3.1 Global Expectorant Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Expectorant Drug Global Expectorant Drug Sales by Region: 2019-2030
3.2.1 Global Expectorant Drug Sales by Region: 2019-2024
3.2.2 Global Expectorant Drug Sales by Region: 2025-2030
3.3 Global Expectorant Drug Global Expectorant Drug Revenue by Region: 2019-2030
3.3.1 Global Expectorant Drug Revenue by Region: 2019-2024
3.3.2 Global Expectorant Drug Revenue by Region: 2025-2030
3.4 North America Expectorant Drug Market Facts & Figures by Country
3.4.1 North America Expectorant Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Expectorant Drug Sales by Country (2019-2030)
3.4.3 North America Expectorant Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Expectorant Drug Market Facts & Figures by Country
3.5.1 Europe Expectorant Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Expectorant Drug Sales by Country (2019-2030)
3.5.3 Europe Expectorant Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Expectorant Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Expectorant Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Expectorant Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Expectorant Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Expectorant Drug Market Facts & Figures by Country
3.7.1 Latin America Expectorant Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Expectorant Drug Sales by Country (2019-2030)
3.7.3 Latin America Expectorant Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Expectorant Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Expectorant Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Expectorant Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Expectorant Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Expectorant Drug Sales by Type (2019-2030)
4.1.1 Global Expectorant Drug Sales by Type (2019-2024)
4.1.2 Global Expectorant Drug Sales by Type (2025-2030)
4.1.3 Global Expectorant Drug Sales Market Share by Type (2019-2030)
4.2 Global Expectorant Drug Revenue by Type (2019-2030)
4.2.1 Global Expectorant Drug Revenue by Type (2019-2024)
4.2.2 Global Expectorant Drug Revenue by Type (2025-2030)
4.2.3 Global Expectorant Drug Revenue Market Share by Type (2019-2030)
4.3 Global Expectorant Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Expectorant Drug Sales by Application (2019-2030)
5.1.1 Global Expectorant Drug Sales by Application (2019-2024)
5.1.2 Global Expectorant Drug Sales by Application (2025-2030)
5.1.3 Global Expectorant Drug Sales Market Share by Application (2019-2030)
5.2 Global Expectorant Drug Revenue by Application (2019-2030)
5.2.1 Global Expectorant Drug Revenue by Application (2019-2024)
5.2.2 Global Expectorant Drug Revenue by Application (2025-2030)
5.2.3 Global Expectorant Drug Revenue Market Share by Application (2019-2030)
5.3 Global Expectorant Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Abbott Laboratories
6.1.1 Abbott Laboratories Corporation Information
6.1.2 Abbott Laboratories Description and Business Overview
6.1.3 Abbott Laboratories Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Abbott Laboratories Expectorant Drug Product Portfolio
6.1.5 Abbott Laboratories Recent Developments/Updates
6.2 Acella Pharmaceuticals LLC
6.2.1 Acella Pharmaceuticals LLC Corporation Information
6.2.2 Acella Pharmaceuticals LLC Description and Business Overview
6.2.3 Acella Pharmaceuticals LLC Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Acella Pharmaceuticals LLC Expectorant Drug Product Portfolio
6.2.5 Acella Pharmaceuticals LLC Recent Developments/Updates
6.3 Astrazeneca Plc.
6.3.1 Astrazeneca Plc. Corporation Information
6.3.2 Astrazeneca Plc. Description and Business Overview
6.3.3 Astrazeneca Plc. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Astrazeneca Plc. Expectorant Drug Product Portfolio
6.3.5 Astrazeneca Plc. Recent Developments/Updates
6.4 Cipla Limited
6.4.1 Cipla Limited Corporation Information
6.4.2 Cipla Limited Description and Business Overview
6.4.3 Cipla Limited Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Limited Expectorant Drug Product Portfolio
6.4.5 Cipla Limited Recent Developments/Updates
6.5 Dabur India Ltd
6.5.1 Dabur India Ltd Corporation Information
6.5.2 Dabur India Ltd Description and Business Overview
6.5.3 Dabur India Ltd Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Dabur India Ltd Expectorant Drug Product Portfolio
6.5.5 Dabur India Ltd Recent Developments/Updates
6.6 Glenmark Pharmaceuticals Limited
6.6.1 Glenmark Pharmaceuticals Limited Corporation Information
6.6.2 Glenmark Pharmaceuticals Limited Description and Business Overview
6.6.3 Glenmark Pharmaceuticals Limited Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Glenmark Pharmaceuticals Limited Expectorant Drug Product Portfolio
6.6.5 Glenmark Pharmaceuticals Limited Recent Developments/Updates
6.7 lohnson and Johnson
6.6.1 lohnson and Johnson Corporation Information
6.6.2 lohnson and Johnson Description and Business Overview
6.6.3 lohnson and Johnson Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 lohnson and Johnson Expectorant Drug Product Portfolio
6.7.5 lohnson and Johnson Recent Developments/Updates
6.8 Merck KGaA
6.8.1 Merck KGaA Corporation Information
6.8.2 Merck KGaA Description and Business Overview
6.8.3 Merck KGaA Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck KGaA Expectorant Drug Product Portfolio
6.8.5 Merck KGaA Recent Developments/Updates
6.9 Novartis International AG
6.9.1 Novartis International AG Corporation Information
6.9.2 Novartis International AG Description and Business Overview
6.9.3 Novartis International AG Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novartis International AG Expectorant Drug Product Portfolio
6.9.5 Novartis International AG Recent Developments/Updates
6.10 Pfizer Inc.
6.10.1 Pfizer Inc. Corporation Information
6.10.2 Pfizer Inc. Description and Business Overview
6.10.3 Pfizer Inc. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pfizer Inc. Expectorant Drug Product Portfolio
6.10.5 Pfizer Inc. Recent Developments/Updates
6.11 Proctor and Gamble Co
6.11.1 Proctor and Gamble Co Corporation Information
6.11.2 Proctor and Gamble Co Expectorant Drug Description and Business Overview
6.11.3 Proctor and Gamble Co Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Proctor and Gamble Co Expectorant Drug Product Portfolio
6.11.5 Proctor and Gamble Co Recent Developments/Updates
6.12 Reckitt Benckiser Group plc
6.12.1 Reckitt Benckiser Group plc Corporation Information
6.12.2 Reckitt Benckiser Group plc Expectorant Drug Description and Business Overview
6.12.3 Reckitt Benckiser Group plc Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Reckitt Benckiser Group plc Expectorant Drug Product Portfolio
6.12.5 Reckitt Benckiser Group plc Recent Developments/Updates
6.13 Sanofi SA
6.13.1 Sanofi SA Corporation Information
6.13.2 Sanofi SA Expectorant Drug Description and Business Overview
6.13.3 Sanofi SA Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Sanofi SA Expectorant Drug Product Portfolio
6.13.5 Sanofi SA Recent Developments/Updates
6.14 The Himalaya Drug Company
6.14.1 The Himalaya Drug Company Corporation Information
6.14.2 The Himalaya Drug Company Expectorant Drug Description and Business Overview
6.14.3 The Himalaya Drug Company Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.14.4 The Himalaya Drug Company Expectorant Drug Product Portfolio
6.14.5 The Himalaya Drug Company Recent Developments/Updates
6.15 Perrigo Company plc
6.15.1 Perrigo Company plc Corporation Information
6.15.2 Perrigo Company plc Expectorant Drug Description and Business Overview
6.15.3 Perrigo Company plc Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Perrigo Company plc Expectorant Drug Product Portfolio
6.15.5 Perrigo Company plc Recent Developments/Updates
6.16 Vernalis plc
6.16.1 Vernalis plc Corporation Information
6.16.2 Vernalis plc Expectorant Drug Description and Business Overview
6.16.3 Vernalis plc Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Vernalis plc Expectorant Drug Product Portfolio
6.16.5 Vernalis plc Recent Developments/Updates
6.17 Tris Pharma Inc.
6.17.1 Tris Pharma Inc. Corporation Information
6.17.2 Tris Pharma Inc. Expectorant Drug Description and Business Overview
6.17.3 Tris Pharma Inc. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Tris Pharma Inc. Expectorant Drug Product Portfolio
6.17.5 Tris Pharma Inc. Recent Developments/Updates
6.18 Aytu BioScience Inc.
6.18.1 Aytu BioScience Inc. Corporation Information
6.18.2 Aytu BioScience Inc. Expectorant Drug Description and Business Overview
6.18.3 Aytu BioScience Inc. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Aytu BioScience Inc. Expectorant Drug Product Portfolio
6.18.5 Aytu BioScience Inc. Recent Developments/Updates
6.19 Mayne Pharma Inc.
6.19.1 Mayne Pharma Inc. Corporation Information
6.19.2 Mayne Pharma Inc. Expectorant Drug Description and Business Overview
6.19.3 Mayne Pharma Inc. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Mayne Pharma Inc. Expectorant Drug Product Portfolio
6.19.5 Mayne Pharma Inc. Recent Developments/Updates
6.20 Taro Pharmaceutical Industries Ltd.
6.20.1 Taro Pharmaceutical Industries Ltd. Corporation Information
6.20.2 Taro Pharmaceutical Industries Ltd. Expectorant Drug Description and Business Overview
6.20.3 Taro Pharmaceutical Industries Ltd. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Taro Pharmaceutical Industries Ltd. Expectorant Drug Product Portfolio
6.20.5 Taro Pharmaceutical Industries Ltd. Recent Developments/Updates
6.21 Amneal Pharmaceuticals LLC
6.21.1 Amneal Pharmaceuticals LLC Corporation Information
6.21.2 Amneal Pharmaceuticals LLC Expectorant Drug Description and Business Overview
6.21.3 Amneal Pharmaceuticals LLC Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Amneal Pharmaceuticals LLC Expectorant Drug Product Portfolio
6.21.5 Amneal Pharmaceuticals LLC Recent Developments/Updates
6.22 Aurobindo Pharma Ltd
6.22.1 Aurobindo Pharma Ltd Corporation Information
6.22.2 Aurobindo Pharma Ltd Expectorant Drug Description and Business Overview
6.22.3 Aurobindo Pharma Ltd Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Aurobindo Pharma Ltd Expectorant Drug Product Portfolio
6.22.5 Aurobindo Pharma Ltd Recent Developments/Updates
6.23 GlaxoSmithKline plc.
6.23.1 GlaxoSmithKline plc. Corporation Information
6.23.2 GlaxoSmithKline plc. Expectorant Drug Description and Business Overview
6.23.3 GlaxoSmithKline plc. Expectorant Drug Sales, Revenue and Gross Margin (2019-2024)
6.23.4 GlaxoSmithKline plc. Expectorant Drug Product Portfolio
6.23.5 GlaxoSmithKline plc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Expectorant Drug Industry Chain Analysis
7.2 Expectorant Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Expectorant Drug Production Mode & Process
7.4 Expectorant Drug Sales and Marketing
7.4.1 Expectorant Drug Sales Channels
7.4.2 Expectorant Drug Distributors
7.5 Expectorant Drug Customers
8 Expectorant Drug Market Dynamics
8.1 Expectorant Drug Industry Trends
8.2 Expectorant Drug Market Drivers
8.3 Expectorant Drug Market Challenges
8.4 Expectorant Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Expectorant Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Expectorant Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Expectorant Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Expectorant Drug Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Expectorant Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Expectorant Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Expectorant Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Expectorant Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Expectorant Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Expectorant Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Expectorant Drug, Product Type & Application
Table 12. Global Key Manufacturers of Expectorant Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Expectorant Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Expectorant Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Expectorant Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Expectorant Drug Sales by Region (2019-2024) & (K Units)
Table 18. Global Expectorant Drug Sales Market Share by Region (2019-2024)
Table 19. Global Expectorant Drug Sales by Region (2025-2030) & (K Units)
Table 20. Global Expectorant Drug Sales Market Share by Region (2025-2030)
Table 21. Global Expectorant Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Expectorant Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Expectorant Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Expectorant Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Expectorant Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Expectorant Drug Sales by Country (2019-2024) & (K Units)
Table 27. North America Expectorant Drug Sales by Country (2025-2030) & (K Units)
Table 28. North America Expectorant Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Expectorant Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Expectorant Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Expectorant Drug Sales by Country (2019-2024) & (K Units)
Table 32. Europe Expectorant Drug Sales by Country (2025-2030) & (K Units)
Table 33. Europe Expectorant Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Expectorant Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Expectorant Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Expectorant Drug Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Expectorant Drug Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Expectorant Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Expectorant Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Expectorant Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Expectorant Drug Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Expectorant Drug Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Expectorant Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Expectorant Drug Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Expectorant Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Expectorant Drug Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Expectorant Drug Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Expectorant Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Expectorant Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Expectorant Drug Sales (K Units) by Type (2019-2024)
Table 51. Global Expectorant Drug Sales (K Units) by Type (2025-2030)
Table 52. Global Expectorant Drug Sales Market Share by Type (2019-2024)
Table 53. Global Expectorant Drug Sales Market Share by Type (2025-2030)
Table 54. Global Expectorant Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Expectorant Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Expectorant Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Expectorant Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Expectorant Drug Price (US$/Unit) by Type (2019-2024)
Table 59. Global Expectorant Drug Price (US$/Unit) by Type (2025-2030)
Table 60. Global Expectorant Drug Sales (K Units) by Application (2019-2024)
Table 61. Global Expectorant Drug Sales (K Units) by Application (2025-2030)
Table 62. Global Expectorant Drug Sales Market Share by Application (2019-2024)
Table 63. Global Expectorant Drug Sales Market Share by Application (2025-2030)
Table 64. Global Expectorant Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Expectorant Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Expectorant Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Expectorant Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Expectorant Drug Price (US$/Unit) by Application (2019-2024)
Table 69. Global Expectorant Drug Price (US$/Unit) by Application (2025-2030)
Table 70. Abbott Laboratories Corporation Information
Table 71. Abbott Laboratories Description and Business Overview
Table 72. Abbott Laboratories Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Abbott Laboratories Expectorant Drug Product
Table 74. Abbott Laboratories Recent Developments/Updates
Table 75. Acella Pharmaceuticals LLC Corporation Information
Table 76. Acella Pharmaceuticals LLC Description and Business Overview
Table 77. Acella Pharmaceuticals LLC Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Acella Pharmaceuticals LLC Expectorant Drug Product
Table 79. Acella Pharmaceuticals LLC Recent Developments/Updates
Table 80. Astrazeneca Plc. Corporation Information
Table 81. Astrazeneca Plc. Description and Business Overview
Table 82. Astrazeneca Plc. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Astrazeneca Plc. Expectorant Drug Product
Table 84. Astrazeneca Plc. Recent Developments/Updates
Table 85. Cipla Limited Corporation Information
Table 86. Cipla Limited Description and Business Overview
Table 87. Cipla Limited Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Cipla Limited Expectorant Drug Product
Table 89. Cipla Limited Recent Developments/Updates
Table 90. Dabur India Ltd Corporation Information
Table 91. Dabur India Ltd Description and Business Overview
Table 92. Dabur India Ltd Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Dabur India Ltd Expectorant Drug Product
Table 94. Dabur India Ltd Recent Developments/Updates
Table 95. Glenmark Pharmaceuticals Limited Corporation Information
Table 96. Glenmark Pharmaceuticals Limited Description and Business Overview
Table 97. Glenmark Pharmaceuticals Limited Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Glenmark Pharmaceuticals Limited Expectorant Drug Product
Table 99. Glenmark Pharmaceuticals Limited Recent Developments/Updates
Table 100. lohnson and Johnson Corporation Information
Table 101. lohnson and Johnson Description and Business Overview
Table 102. lohnson and Johnson Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. lohnson and Johnson Expectorant Drug Product
Table 104. lohnson and Johnson Recent Developments/Updates
Table 105. Merck KGaA Corporation Information
Table 106. Merck KGaA Description and Business Overview
Table 107. Merck KGaA Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Merck KGaA Expectorant Drug Product
Table 109. Merck KGaA Recent Developments/Updates
Table 110. Novartis International AG Corporation Information
Table 111. Novartis International AG Description and Business Overview
Table 112. Novartis International AG Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Novartis International AG Expectorant Drug Product
Table 114. Novartis International AG Recent Developments/Updates
Table 115. Pfizer Inc. Corporation Information
Table 116. Pfizer Inc. Description and Business Overview
Table 117. Pfizer Inc. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Pfizer Inc. Expectorant Drug Product
Table 119. Pfizer Inc. Recent Developments/Updates
Table 120. Proctor and Gamble Co Corporation Information
Table 121. Proctor and Gamble Co Description and Business Overview
Table 122. Proctor and Gamble Co Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Proctor and Gamble Co Expectorant Drug Product
Table 124. Proctor and Gamble Co Recent Developments/Updates
Table 125. Reckitt Benckiser Group plc Corporation Information
Table 126. Reckitt Benckiser Group plc Description and Business Overview
Table 127. Reckitt Benckiser Group plc Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Reckitt Benckiser Group plc Expectorant Drug Product
Table 129. Reckitt Benckiser Group plc Recent Developments/Updates
Table 130. Sanofi SA Corporation Information
Table 131. Sanofi SA Description and Business Overview
Table 132. Sanofi SA Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Sanofi SA Expectorant Drug Product
Table 134. Sanofi SA Recent Developments/Updates
Table 135. The Himalaya Drug Company Corporation Information
Table 136. The Himalaya Drug Company Description and Business Overview
Table 137. The Himalaya Drug Company Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. The Himalaya Drug Company Expectorant Drug Product
Table 139. The Himalaya Drug Company Recent Developments/Updates
Table 140. Perrigo Company plc Corporation Information
Table 141. Perrigo Company plc Description and Business Overview
Table 142. Perrigo Company plc Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Perrigo Company plc Expectorant Drug Product
Table 144. Perrigo Company plc Recent Developments/Updates
Table 145. Vernalis plc Corporation Information
Table 146. Vernalis plc Description and Business Overview
Table 147. Vernalis plc Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Vernalis plc Expectorant Drug Product
Table 149. Vernalis plc Recent Developments/Updates
Table 150. Tris Pharma Inc. Corporation Information
Table 151. Tris Pharma Inc. Description and Business Overview
Table 152. Tris Pharma Inc. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Tris Pharma Inc. Expectorant Drug Product
Table 154. Tris Pharma Inc. Recent Developments/Updates
Table 155. Aytu BioScience Inc. Corporation Information
Table 156. Aytu BioScience Inc. Description and Business Overview
Table 157. Aytu BioScience Inc. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Aytu BioScience Inc. Expectorant Drug Product
Table 159. Aytu BioScience Inc. Recent Developments/Updates
Table 160. Mayne Pharma Inc. Corporation Information
Table 161. Mayne Pharma Inc. Description and Business Overview
Table 162. Mayne Pharma Inc. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. Mayne Pharma Inc. Expectorant Drug Product
Table 164. Mayne Pharma Inc. Recent Developments/Updates
Table 165. Taro Pharmaceutical Industries Ltd. Corporation Information
Table 166. Taro Pharmaceutical Industries Ltd. Description and Business Overview
Table 167. Taro Pharmaceutical Industries Ltd. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Taro Pharmaceutical Industries Ltd. Expectorant Drug Product
Table 169. Taro Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 170. Amneal Pharmaceuticals LLC Corporation Information
Table 171. Amneal Pharmaceuticals LLC Description and Business Overview
Table 172. Amneal Pharmaceuticals LLC Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 173. Amneal Pharmaceuticals LLC Expectorant Drug Product
Table 174. Amneal Pharmaceuticals LLC Recent Developments/Updates
Table 175. Aurobindo Pharma Ltd Corporation Information
Table 176. Aurobindo Pharma Ltd Description and Business Overview
Table 177. Aurobindo Pharma Ltd Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 178. Aurobindo Pharma Ltd Expectorant Drug Product
Table 179. Aurobindo Pharma Ltd Recent Developments/Updates
Table 180. GlaxoSmithKline plc. Corporation Information
Table 181. GlaxoSmithKline plc. Description and Business Overview
Table 182. GlaxoSmithKline plc. Expectorant Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 183. GlaxoSmithKline plc. Expectorant Drug Product
Table 184. GlaxoSmithKline plc. Recent Developments/Updates
Table 185. Key Raw Materials Lists
Table 186. Raw Materials Key Suppliers Lists
Table 187. Expectorant Drug Distributors List
Table 188. Expectorant Drug Customers List
Table 189. Expectorant Drug Market Trends
Table 190. Expectorant Drug Market Drivers
Table 191. Expectorant Drug Market Challenges
Table 192. Expectorant Drug Market Restraints
Table 193. Research Programs/Design for This Report
Table 194. Key Data Information from Secondary Sources
Table 195. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Expectorant Drug
Figure 2. Global Expectorant Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Expectorant Drug Market Share by Type in 2023 & 2030
Figure 4. Oral Solid Product Picture
Figure 5. Oral Liquid Product Picture
Figure 6. Inhalants Product Picture
Figure 7. Global Expectorant Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Expectorant Drug Market Share by Application in 2023 & 2030
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Other
Figure 12. Global Expectorant Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Expectorant Drug Market Size (2019-2030) & (US$ Million)
Figure 14. Global Expectorant Drug Sales (2019-2030) & (K Units)
Figure 15. Global Expectorant Drug Average Price (US$/Unit) & (2019-2030)
Figure 16. Expectorant Drug Report Years Considered
Figure 17. Expectorant Drug Sales Share by Manufacturers in 2023
Figure 18. Global Expectorant Drug Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Expectorant Drug Players: Market Share by Revenue in 2023
Figure 20. Expectorant Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Expectorant Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Expectorant Drug Sales Market Share by Country (2019-2030)
Figure 23. North America Expectorant Drug Revenue Market Share by Country (2019-2030)
Figure 24. United States Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Expectorant Drug Sales Market Share by Country (2019-2030)
Figure 27. Europe Expectorant Drug Revenue Market Share by Country (2019-2030)
Figure 28. Germany Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Netherlands Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Expectorant Drug Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Expectorant Drug Revenue Market Share by Region (2019-2030)
Figure 35. China Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Expectorant Drug Sales Market Share by Country (2019-2030)
Figure 43. Latin America Expectorant Drug Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Expectorant Drug Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Expectorant Drug Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Expectorant Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Expectorant Drug by Type (2019-2030)
Figure 53. Global Revenue Market Share of Expectorant Drug by Type (2019-2030)
Figure 54. Global Expectorant Drug Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Expectorant Drug by Application (2019-2030)
Figure 56. Global Revenue Market Share of Expectorant Drug by Application (2019-2030)
Figure 57. Global Expectorant Drug Price (US$/Unit) by Application (2019-2030)
Figure 58. Expectorant Drug Value Chain
Figure 59. Expectorant Drug Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
